Salomon Azoulay
Fortune : 815 249 $ au 30/06/2026
Fortune : 815 249 $ au 30/06/2026
Salomon Azoulay currently works at MBX Biosciences, Inc., as Chief Medical Officer from 2024.
Dr. Azoulay also formerly worked at Pfizer Essential Health, as Chief Medical Officer from 2013 to 2018, Sumitomo Pharma UK Holdings Ltd., as Chief Medical Officer from 2021 to 2023, and Roivant Sciences, Inc., as Chief Medical Officer from 2018 to 2020.
Dr. Azoulay received his undergraduate degree and doctorate degree from Sorbonne Université.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 08/05/2026 | 14 769 ( 0,03% ) | 815 249 $ | 30/06/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| MBX BIOSCIENCES, INC. | Directeur Technique/Scientifique/R&D | 01/06/2024 |
| Sociétés | Poste | Fin |
|---|---|---|
Sumitomo Pharma UK Holdings Ltd.
Sumitomo Pharma UK Holdings Ltd. Pharmaceuticals: MajorHealth Technology Operates as a holding company with interests in provides biopharmaceutical services | Directeur Technique/Scientifique/R&D | 01/07/2023 |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Directeur Technique/Scientifique/R&D | 01/12/2020 |
Pfizer Essential Health
Pfizer Essential Health Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Directeur Technique/Scientifique/R&D | 01/05/2018 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 5 |
|---|---|
Sorbonne Université
Sorbonne Université Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pfizer Essential Health
Pfizer Essential Health Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Health Technology |
MBX Biosciences, Inc.
MBX Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company focused on discovery and development of novel precision peptide therapies for endocrine & metabolic disorders | Health Technology |
Sumitomo Pharma UK Holdings Ltd.
Sumitomo Pharma UK Holdings Ltd. Pharmaceuticals: MajorHealth Technology Operates as a holding company with interests in provides biopharmaceutical services | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national